CN106581130A - Bone density increment tablet and preparation process thereof - Google Patents
Bone density increment tablet and preparation process thereof Download PDFInfo
- Publication number
- CN106581130A CN106581130A CN201611096891.0A CN201611096891A CN106581130A CN 106581130 A CN106581130 A CN 106581130A CN 201611096891 A CN201611096891 A CN 201611096891A CN 106581130 A CN106581130 A CN 106581130A
- Authority
- CN
- China
- Prior art keywords
- parts
- bone density
- bone
- extract
- piece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037182 bone density Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 22
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 11
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 11
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 11
- 239000011812 mixed powder Substances 0.000 claims description 10
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 229940097275 indigo Drugs 0.000 claims description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims description 3
- 239000004149 tartrazine Substances 0.000 claims description 3
- 229960000943 tartrazine Drugs 0.000 claims description 3
- 235000012756 tartrazine Nutrition 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000010409 thin film Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- HGWOWDFNMKCVLG-UHFFFAOYSA-N [O--].[O--].[Ti+4].[Ti+4] Chemical compound [O--].[O--].[Ti+4].[Ti+4] HGWOWDFNMKCVLG-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 8
- 239000011575 calcium Substances 0.000 abstract description 8
- 229910052791 calcium Inorganic materials 0.000 abstract description 8
- 208000010392 Bone Fractures Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 206010061363 Skeletal injury Diseases 0.000 abstract 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical class N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001116742 Drynaria Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- -1 hydroxypropyl methyl Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a bone density increment tablet and a preparation process thereof. Active components mainly include rhizoma drynariae extract, cortex eucommiae extract, calcium carbonate, D-glucosamine hydrochloride, chondroitin sulfate, and chitosan oligosaccharide. The drug effect is quick, clinical symptoms disappear quickly, toxic and side effects are small, and the bone calcium content or the bone density is remarkably increased; and the treatment course is short, the pain is small, the expense is low, healing can be realized in one time, and the harm caused by bone fracture, bone disintegration and bone injury can be eliminated.
Description
Technical field
The invention belongs to technical field of health care food, and in particular to one kind increases bone density piece and its preparation technology.
Background technology
Bone density, is an important symbol of bone mass, reflects osteoporosises degree, is the important of prediction fracture risk
Foundation.In daily life, fracture and osteoporosises have become common disease, and old man and child are easy to due to itself system feature
Fracture, mainly this disease is treated with reset, fixed, functional exercise in the treatment Chinese and western medicine of fracture.And it is osteoporotic
Easily sending out crowd has：A variety of causes to the low man of sex hormone level, female adult, over-65s women, more than 70 years old male, 65
Year following postmenopausal women or less than 70 years old elderly men, the man, the female adult that have fragility fractures history.Sufferers of osteoporosis face is always
Subject the pain that disease is brought, and the impact physically after textured bone and the mental pressure that causes.At present, sclerotin is dredged
There is no fracture and do not need surgical intervention in loose patient, typically based on Drug therapy.
The content of the invention
According to above the deficiencies in the prior art, the technical problem to be solved is to propose a kind of increase bone density piece
And its preparation technology, evident in efficacy, treatment cycle is short, reduces medical expense, improves therapeutic effect, simplifies Therapeutic Method.
The selected following pure Chinese medicine material Jing scientific composition compatibilities of the present invention, make Chinese medicine preparation (by weight), match somebody with somebody substantially
Side is as follows：Rhizoma Drynariae extract 2-3 parts, Cortex Eucommiae extract 4-5 parts, Calcium Carbonate 20-25 part, D-Glucosamine Hydrochloride 25-
30 parts, chondroitin sulfate 5-6 parts, oligochitosan 3-4 parts.
The present invention provide it is a kind of increase bone density piece, be characterised by by following material by ratio of weight and the number of copies made by activity
Composition：2.8 parts of Rhizoma Drynariae extract, 4.8 parts of Cortex Eucommiae extract, 22 parts of Calcium Carbonate, 28 parts of D-Glucosamine Hydrochloride, sulphuric acid
5.6 parts of chrondroitin, 3.2 parts of oligochitosan.
The pharmacology analysis of product of the present invention：Rhizoma Drynariae and Cortex Eucommiae extract all can invigorating the liver and kidney, bone and muscle strengthening.Rhizoma Drynariae can change
Kind bone ultrastructure, improves bone mass；The calcitonin in Peripheral Blood is improved, so as to play the osteoporotic effect for the treatment of.Bone
Broken complementary energy promotes absorption of the bone to calcium, improves blood calcium and serum phosphorus levels, is conducive to bone calcification and bone mineral to be formed.Drynaria Rhizome
There is obvious facilitation to the calcium phosphorus precipitation of Embryo Gallus domesticus collagen base, improve the activity of acid phosphatase in tissue, promote albumen many
The synthesis of sugar, suppresses collage synthesis, can improve the function of cartilage erythrocyte, postpones cell regeneration and becomes, and reduces osteoarthritis disease
Osteoarthritis are had good therapeutical effect by variability.Folium Eucommiae can make osteoblastic proliferation, hence it is evident that improve ALP secretions, Folium Eucommiae
Extract can promote Oesteoblast growth, strengthen bone formation, and Folium Eucommiae extract can reduce calcium and bone phosphorus in bone and lose, and promote calcium
Deposition with phosphorus in bone.D-Glucosamine Hydrochloride, chondroitin sulfate have the function that increases bone density well and compared with
High safety.D-Glucosamine Hydrochloride can be repaired as chitin to the articular cartilage being damaged, and be protected
Shield osteoarthrosis.Chondroitin sulfate can promote the nutrition needed for bone growth, reparation osseous tissue, supply osteogenesis, participate in skeleton
Metabolism.Oligochitosan can promote osteoblastic activity to increase so that bone morphogenetic protein (BMP) expression strengthens,
While expression time shifts to an earlier date, so as to promote bone cell growth.
The concrete preparation technology of medicine of the present invention：
Take Rhizoma Drynariae extract, the fine powder of Cortex Eucommiae extract crosses 80-100 mesh pharmacopeia sieve, be thoroughly mixed together and mixed
Powder 1 is closed, D-Glucosamine Hydrochloride, Calcium Carbonate and starch that 80-100 mesh pharmacopeia is sieved was added in mixed powder 1, together
It is sufficiently mixed, obtains mixed powder 2, the ethanol for taking 65% is obtained soft material, and soft material crosses the granulation of 20 mesh sieves and obtains wet granular, by wet granular
6-8 hours are dried in the environment of 60-70 DEG C, the water content to wet granular crosses 18 mesh sieves below 5%, then and obtains dry
Grain.Weigh oligochitosan, chondroitin sulfate and silicon dioxide and cross and mixed powder 3 is mixed to get after 80 mesh sieves, by mixed powder 3 and dry particl
After mixing, add magnesium stearate and obtain final mixture.Total mixture tabletting obtains plain piece, obtains in plain piece outer wrapping thin film
Film coated tablets.Coating powder is obtained film coating liquid with 70% ethanol solution, and in coating process, inlet temperature is 60-80 DEG C, piece bed
Temperature is 40-45 DEG C, and pot rotating speed is 4-8r/min, and spray gun pressure is 5-6kg, and coating flow velocity is 120-180g/min.
Coating powder consists of polyvinyl alcohol, titanium dioxide, Pulvis Talci, Polyethylene Glycol, soybean phospholipid, hydroxypropyl methyl fiber
Plain, indigo aluminum lake, tartrazine aluminum lake, Brilliant blue aluminum lake.
In the above adjuvant starch be 17.2 parts, silicon dioxide be 0.6 part, 0.8 part of magnesium stearate, 1.7 parts of coating powder.
The pharmacological property of medicine of the present invention is proved by tests below：Promulgate according to Ministry of Public Health《Health food check with
Assessment technique specification》In increase bone substance density improving function test method.Select three dosage groups, i.e., 150,300 and 600mg/kg
Bw groups (are respectively equivalent to 5 times, 10 times and 20 times of this product human intaking amount).Following table one is increase bone density piece to rat
The impact of bone density and calcium content of bone.
| Group | Animal number of elements | Right bone calcium content of femur/(mg/g) | Fl bone density/(g/cm2) |
| Model control group | 10 | 229.06±20.12 | 0.1901±0.0079 |
| Sham operated rats | 10 | 240.65±11.59 | 0.2086±0.0190 |
| 150mg/kg·bw | 10 | 231.56±10.36 | 0.2058±0.0162 |
| 300mg/kg·bw | 10 | 232.48±7.45 | 0.2051±0.0126 |
| 600mg/kg·bw | 10 | 230.79±12.22 | 0.2045±0.0064 |
Model above matched group fl bone density is substantially less than sham operated rats (P ＜ 0.01)；3 dosage groups of this product
Fl bone density (P ＜ 0.05) significantly raised compared with model control group；The right bone calcium content of femur of 3 dosage groups of material object and model pair
According between group without significant difference (P ＞ 0.05).Compared with model control group by the right femoral bone mass of 3 dosage groups in kind, had
Increase trend, but not statistically significant (P ＞ 0.05)；It is bright compared with model control group by the fl bone density of 3 dosage groups in kind
It is aobvious to raise (P ＜ 0.05).Therefore, according to evaluation criterion, the bone density piece of the present invention has the function of increasing bone density.
Specific embodiment
Below by the description to embodiment, shape, the structure of for example involved each component of specific embodiment of the invention
Make, the mutual alignment between each several part and annexation, the effect of each several part and operation principle, manufacturing process and the side of operating with
Method etc., is described in further detail, and has completeer to inventive concept of the invention, technical scheme to help those skilled in the art
Whole, accurate and deep understanding.
Specific embodiment one：2.8 parts of Rhizoma Drynariae extract, 4.8 parts of Cortex Eucommiae extract, 22 parts of Calcium Carbonate, D- aminoglucoses
28 parts of sugared hydrochlorate, 5.6 parts of chondroitin sulfate, 3.2 parts of oligochitosan.It is 0.6 part for 17.2 parts, silicon dioxide that adjuvant is starch,
0.8 part of magnesium stearate, 1.7 parts of coating powder, wherein coating powder consist of polyvinyl alcohol, titanium dioxide, Pulvis Talci, Polyethylene Glycol,
Soybean phospholipid, hydroxypropyl methyl cellulose, indigo aluminum lake, tartrazine aluminum lake, Brilliant blue aluminum lake.
Specific embodiment two：2 parts of Rhizoma Drynariae extract, 5 parts of Cortex Eucommiae extract, 25 parts of Calcium Carbonate, D-glucosamine salt
25 parts of hydrochlorate, 6 parts of chondroitin sulfate, 4 parts of oligochitosan.It is 0.6 part for 17.2 parts, silicon dioxide that adjuvant is starch, magnesium stearate
0.8 part, 1.7 parts of coating powder.
Specific embodiment three：3 parts of Rhizoma Drynariae extract, 4 parts of Cortex Eucommiae extract, 20 parts of Calcium Carbonate, D-glucosamine salt
30 parts of hydrochlorate, 5 parts of chondroitin sulfate, 4 parts of oligochitosan.It is 0.6 part for 17.2 parts, silicon dioxide that adjuvant is starch, magnesium stearate
0.8 part, 1.7 parts of coating powder.
Specific embodiment four：2.5 parts of Rhizoma Drynariae extract, 4.5 parts of Cortex Eucommiae extract, 22.5 parts of Calcium Carbonate, D- amino Portugal
Grape 27.5 parts of hydrochlorate of sugar, 5.5 parts of chondroitin sulfate, 3.4 parts of oligochitosan.It is 0.6 for 17.2 parts, silicon dioxide that adjuvant is starch
Part, 0.8 part of magnesium stearate, 1.7 parts of coating powder,
The present invention is exemplarily described above, it is clear that the present invention is implemented and is not subject to the restrictions described above,
As long as the improvement of the various unsubstantialities that method of the present invention design and technical scheme are carried out is employed, or it is not improved by this
Bright design and technical scheme directly applies to other occasions, within protection scope of the present invention.The protection of the present invention
The protection domain that scope should be limited by claims is defined.
Claims (6)
1. it is a kind of to increase bone density piece, be characterised by active component by following material by ratio of weight and the number of copies made by：Rhizoma Drynariae is carried
Take thing 2-3 parts, Cortex Eucommiae extract 4-5 parts, Calcium Carbonate 20-25 part, D-Glucosamine Hydrochloride 25-30 parts, chondroitin sulfate
5-6 parts, oligochitosan 3-4 parts.
2. increase bone density piece according to claim 1, is characterised by active component by following material by ratio of weight and the number of copies
Made by：2.8 parts of Rhizoma Drynariae extract, 4.8 parts of Cortex Eucommiae extract, 22 parts of Calcium Carbonate, 28 parts of D-Glucosamine Hydrochloride, sulfur
5.6 parts of aching and limp ossein, 3.2 parts of oligochitosan.
3. increase bone density piece according to claim 1, is characterised by also making by ratio of weight and the number of copies including following material
Adjuvant：17.2 parts of starch, 0.6 part of silicon dioxide, 0.8 part of magnesium stearate, 1.7 parts of coating powder.
4. increase bone density piece according to claim 3, is characterised by that the coating powder consists of polyvinyl alcohol, titanium dioxide
Titanium, Pulvis Talci, Polyethylene Glycol, soybean phospholipid, hydroxypropyl methyl cellulose, indigo aluminum lake, tartrazine aluminum lake, light blue aluminum color
Form sediment.
5. the one kind according to any one in claim 1-4 increases bone density piece, it is characterised in that described bone density
Piece is tablet.
6. it is a kind of increase bone density piece preparation technology, it is characterised in that comprise the steps：Take Rhizoma Drynariae extract, the Cortex Eucommiae
The fine powder of extract crosses 80-100 mesh pharmacopeia sieve, is thoroughly mixed together and obtains mixed powder 1, and in mixed powder 1 80- was added
D-Glucosamine Hydrochloride, Calcium Carbonate and starch that 100 mesh pharmacopeia are sieved, are sufficiently mixed together, obtain mixed powder 2, take
65% ethanol is obtained soft material, and soft material crosses the granulation of 20 mesh sieves and obtains wet granular, and wet granular is dried in the environment of 60-70 DEG C 6-
8 hours, the water content to wet granular crossed 18 mesh sieves and obtains dry particl below 5%, then；Weigh oligochitosan, chondroitin sulfate
Cross with silicon dioxide and mixed powder 3 is mixed to get after 80 mesh sieves, after mixed powder 3 is mixed with dry particl, add magnesium stearate and obtain
To final mixture.Total mixture tabletting obtains plain piece, and in plain piece outer wrapping thin film Film coated tablets are obtained；The coating powder is used
70% ethanol solution is obtained film coating liquid, and in coating process, inlet temperature is 60-80 DEG C, and piece bed tempertaure is 40-45 DEG C, pot
Body rotating speed is 4-8r/min, and spray gun pressure is 5-6kg, and coating flow velocity is 120-180g/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611096891.0A CN106581130A (en) | 2016-12-02 | 2016-12-02 | Bone density increment tablet and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611096891.0A CN106581130A (en) | 2016-12-02 | 2016-12-02 | Bone density increment tablet and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581130A true CN106581130A (en) | 2017-04-26 |
Family
ID=58596868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611096891.0A Pending CN106581130A (en) | 2016-12-02 | 2016-12-02 | Bone density increment tablet and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581130A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108144047A (en) * | 2017-12-30 | 2018-06-12 | 广州润虹医药科技股份有限公司 | A kind of health composition of chitosan-containing for increasing bone density and application thereof |
| CN108685943A (en) * | 2018-07-19 | 2018-10-23 | 深圳极醇健康产业股份有限公司 | A kind of tablet and preparation method thereof increasing bone density |
| CN110115385A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of strength osteocomma increasing bone density and its production method |
| CN112806579A (en) * | 2021-01-18 | 2021-05-18 | 湖南慧泽生物医药科技有限公司 | Formula food for gout patients |
| CN116270792A (en) * | 2023-03-24 | 2023-06-23 | 芜湖市诺康生物科技有限公司 | Composition for increasing bone mineral density by combining aminosugar and traditional Chinese medicinal materials and production process thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030879A (en) * | 2015-05-15 | 2015-11-11 | 江西师范大学 | Chitosan oligosaccharide bone-fortifying health-caring product and production method thereof |
| CN105054035A (en) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | Health-care product capable of improving bone density and preparation method of health-care product |
-
2016
- 2016-12-02 CN CN201611096891.0A patent/CN106581130A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030879A (en) * | 2015-05-15 | 2015-11-11 | 江西师范大学 | Chitosan oligosaccharide bone-fortifying health-caring product and production method thereof |
| CN105054035A (en) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | Health-care product capable of improving bone density and preparation method of health-care product |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108144047A (en) * | 2017-12-30 | 2018-06-12 | 广州润虹医药科技股份有限公司 | A kind of health composition of chitosan-containing for increasing bone density and application thereof |
| CN110115385A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of strength osteocomma increasing bone density and its production method |
| CN108685943A (en) * | 2018-07-19 | 2018-10-23 | 深圳极醇健康产业股份有限公司 | A kind of tablet and preparation method thereof increasing bone density |
| CN112806579A (en) * | 2021-01-18 | 2021-05-18 | 湖南慧泽生物医药科技有限公司 | Formula food for gout patients |
| CN116270792A (en) * | 2023-03-24 | 2023-06-23 | 芜湖市诺康生物科技有限公司 | Composition for increasing bone mineral density by combining aminosugar and traditional Chinese medicinal materials and production process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106581130A (en) | Bone density increment tablet and preparation process thereof | |
| CN103829238A (en) | Blood lipid lowering health food and preparation method thereof | |
| CN101648018A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| CN104605226A (en) | Healthcare product with function of increasing bone mineral density | |
| CN103520439B (en) | Traditional Chinese medicine for treating heat-toxicity accumulation type chronic osteomyelitis and preparation method thereof | |
| CN106822377B (en) | Compound osteitis cataplasm patch and preparation method thereof | |
| CN107823634A (en) | Treatment medicine for treating osteoporosis based on marine polysaccharide | |
| CN107156849A (en) | A kind of joint care composition and its application containing curcumin | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| CN100363021C (en) | Use of cajan seed and its extract in preparing medicine for treating osteal arthritis | |
| CN104524247A (en) | Pharmaceutical composition for treating migraine and application thereof | |
| CN101648015A (en) | Chinese medicinal composition for treating glaucoma and application thereof | |
| CN101549025B (en) | Traditional Chinese medicine for treating cancer | |
| CN104524524B (en) | Medicine treating osteoporosis and preparing method | |
| CN102526639A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN104587456A (en) | Production process for health product capable of increasing bone mineral density | |
| CN102949712A (en) | Chinese and western composite medicine for treating neoplastic diseases | |
| CN113115953A (en) | Health food for increasing bone mineral density and preparation method thereof | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| CN100408055C (en) | Chinese medicinal composition for treating traumatic diseases, its preparation method and quality control method | |
| CN100471507C (en) | Traditional Chinese medicine prepn. for treating osteoporosis | |
| CN104888192A (en) | Sea cucumber glucosamine preparation for increasing bone mineral density, and production method thereof | |
| CN103251935A (en) | Medicinal composite containing cornu cervi pantotrichum and application thereof | |
| CN115869384B (en) | Peptide-containing pharmaceutical composition for promoting bone replacement improvement | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |